AI-driven drug development company Absci has partnered with Memorial Sloan Kettering Cancer Center (MSK) to create up to six novel cancer therapeutics using GenAI.
The collaboration will combine Absci's AI and wet lab technologies with MSK's oncology expertise. MSK will identify cancer targets, while Absci will design antibodies using AI. This partnership aims to accelerate the discovery and development of new cancer treatments, with promising targets for preclinical development expected by the end of 2024.
This collaboration is Absci's first with a non-profit research institute, adding to its existing collaborations with major companies like AstraZeneca, Merck, and NVIDIA. The partnership reflects a broader trend of using AI for drug discovery and development, particularly in oncology.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.